Celldex Therapeutics CLDX Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingAssets.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's increase (decrease) in other operating assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's increase (decrease) in other operating assets?
- Celldex Therapeutics (CLDX) reported increase (decrease) in other operating assets of $2.08M in Q1 2026.
- How has Celldex Therapeutics's increase (decrease) in other operating assets changed year-over-year?
- Celldex Therapeutics's increase (decrease) in other operating assets increased by 213.6% year-over-year, from $662K to $2.08M.
- What is the long-term trend for Celldex Therapeutics's increase (decrease) in other operating assets?
- Over 3 years (2021 to 2025), Celldex Therapeutics's increase (decrease) in other operating assets has grown at a 797.2% compound annual growth rate (CAGR), from $5K to $3.61M.
- What does increase (decrease) in other operating assets mean?
- This captures the net change in miscellaneous assets that are not classified as loans, securities, or property, plant, and equipment. It often includes items like accrued interest receivables, prepaid expenses, and other short-term operational assets.